41 results
8-K
EX-99.2
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
Kineta data and analysis on file
28 Source: Globaldata: Epidemiology Market Size Forecast - 2027 Incident cases diagnosed (N) 8MM: US, France, Germany
8-K
EX-99.1
KA
Kineta Inc
5 Jan 24
Regulation FD Disclosure
4:30pm
after treatment
24 Source: Globaldata: Epidemiology Market Size Forecast - 2027 Incident cases diagnosed (N) 8MM: US, France, Germany, Italy, Spain, UK
8-K
EX-99.2
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
Source: Globaldata: Epidemiology Market Size Forecast - 2027 Incident cases diagnosed (N) 8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban
8-K
EX-99.2
2xulp2n0b5u 7p
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-10.1
82j6bkx60g0
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
enff7q7
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
ixyxmnc 8x
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-10.1
1arfk6et1wmrrcx 28
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-99.5
0xtypx h00jmb
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.6
mmfk1lrl auj8133ztb8
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm